Please login to the form below

Not currently logged in
Email:
Password:

Pfizer to shut down two UK manufacturing sites

Over 370 jobs at the north London and Hampshire plants are at risk
Pfizer

Pfizer is to close two of its three UK manufacturing sites by 2020, leaving over 370 jobs hanging in the balance.

The New York City-based pharma giant said that the decision was “in no way related” to the UK's vote to leave the European Union in June this year and commended the “excellent work” of its employees at both locations.

Instead, a spokesperson for the firm said the plans are part of an ongoing review of Pfizer's worldwide operations, which will also see its headquarters moved for the first time in over 50 years.

Biosimilar specialist Hospira's site at Park Royal, north London is set to close down by May 2017, the firm having been acquired by Pfizer last year in a $15bn deal.

Pfizer has already sold off Hospira's infusion therapy business unit, bringing in $600m in cash and $400m in stock from buyer ICU Medical as it looks to focus on pharmaceuticals.

Its packaging and distribution site in Havant, Hampshire is also set to close, with the majority of the job losses expected here.

Pfizer has, however, committed to supporting the affected staff who will be considered for “a limited number of positions elsewhere within Pfizer”.

The firm is looking to sell the Havant plant as an ongoing pharmaceutical manufacturing facility and plans to transfer the work undertaken there to its Puurs, Belgium site.

It will work with existing customers to ensure all contracts are fulfilled without any disruption to the supply of its products.

Article by
Rebecca Clifford

10th November 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics